[{"id":"6681fc89-1508-441a-b250-9c07d906a33e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159672","created_at":"2025-09-13T08:45:49.996Z","updated_at":"2025-09-13T08:45:49.996Z","phase":"","brief_title":"Cohort Study on Nutritional, Metabolic, and Volumetric Assessment After Pancreaticoduodenectomy","source_id_and_acronym":"NCT07159672","lead_sponsor":"Marco Aurélio Ribeiro, PhD","biomarkers":" CXCL8 • IL4","pipe":"","alterations":" ","tags":["CXCL8 • IL4"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-09-08"},{"id":"95af4e00-bb4a-434c-a34b-1b5eb891c198","acronym":"","url":"https://clinicaltrials.gov/study/NCT04550481","created_at":"2025-08-02T14:05:48.713Z","updated_at":"2025-08-02T14:05:48.713Z","phase":"Phase 2","brief_title":"Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study","source_id_and_acronym":"NCT04550481","lead_sponsor":"Northwestern University","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-07-29"},{"id":"7152824f-51d6-434a-a17c-b34a21be5fde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07037004","created_at":"2025-06-28T13:42:45.741Z","updated_at":"2025-06-28T13:42:45.741Z","phase":"Phase 2","brief_title":"Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","source_id_and_acronym":"NCT07037004","lead_sponsor":"City of Hope Medical Center","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/04/2026","start_date":" 05/04/2026","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2025-06-25"},{"id":"2d035165-64ed-42fd-8dd4-3556c0edcbcd","acronym":"NCI-2018-01593","url":"https://clinicaltrials.gov/study/NCT03637816","created_at":"2025-06-07T14:41:51.112Z","updated_at":"2025-06-07T14:41:51.112Z","phase":"Phase 1","brief_title":"Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03637816 - NCI-2018-01593","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CXCL8 • IGF1 • IL6R","pipe":"","alterations":" ","tags":["CXCL8 • IGF1 • IL6R"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-06-04"},{"id":"eaf42744-6561-4355-bc41-de5a8068b118","acronym":"PILDI","url":"https://clinicaltrials.gov/study/NCT06923787","created_at":"2025-09-06T17:46:28.223Z","updated_at":"2025-09-06T17:46:28.223Z","phase":"Phase 3","brief_title":"Effect of Lidocaine or Dexamethasone on Cancer Immune Response- the PILDI Study","source_id_and_acronym":"NCT06923787 - PILDI","lead_sponsor":"Institute of Oncology Ljubljana","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-04-11"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"c18480ea-e56b-4074-80ac-afaf290dce63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04556045","created_at":"2021-01-18T21:46:44.852Z","updated_at":"2025-02-25T16:53:16.785Z","phase":"","brief_title":"Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer","source_id_and_acronym":"NCT04556045","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-04"},{"id":"7a194544-769d-4908-bc9c-7b8bbff6762b","acronym":"NCI-2012-01247","url":"https://clinicaltrials.gov/study/NCT01684397","created_at":"2023-11-30T22:15:06.234Z","updated_at":"2025-02-25T13:17:55.736Z","phase":"Phase 1/2","brief_title":"Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer","source_id_and_acronym":"NCT01684397 - NCI-2012-01247","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • pazopanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/21/2012","start_date":" 11/21/2012","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2024-11-06"},{"id":"c99db0f5-d093-438e-9611-dd52b6a2e714","acronym":"","url":"https://clinicaltrials.gov/study/NCT06471270","created_at":"2025-02-26T14:18:15.906Z","updated_at":"2025-02-26T14:18:15.906Z","phase":"","brief_title":"Validation of Salivary Proteomic Biomarkers for Early Detection of Oral Cancer in Egyptian Population","source_id_and_acronym":"NCT06471270","lead_sponsor":"British University In Egypt","biomarkers":" IL6 • CXCL8","pipe":"","alterations":" ","tags":["IL6 • CXCL8"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2023","start_date":" 07/15/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/15/2024","study_completion_date":" 03/15/2024","last_update_posted":"2024-06-24"},{"id":"c1b27e69-5cb6-4c7f-a2c7-df42fb2ed239","acronym":"CYTOK-AZA","url":"https://clinicaltrials.gov/study/NCT06439199","created_at":"2024-06-08T04:34:20.475Z","updated_at":"2024-07-02T16:34:59.405Z","phase":"","brief_title":"Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy","source_id_and_acronym":"NCT06439199 - CYTOK-AZA","lead_sponsor":"Nantes University Hospital","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/15/2024","start_date":" 06/15/2024","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-03"},{"id":"853b2c7a-ae04-4c10-89b6-0e2751505bec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04812652","created_at":"2024-05-04T04:26:52.545Z","updated_at":"2024-07-02T16:35:06.634Z","phase":"","brief_title":"Digitally Distributed Yoga for Women Treated for Breast Cancer","source_id_and_acronym":"NCT04812652","lead_sponsor":"Region Örebro County","biomarkers":" TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 229","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-01"},{"id":"0a0424c7-9b19-4e63-af51-633e80f32ff5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02782949","created_at":"2021-01-18T13:39:03.685Z","updated_at":"2024-07-02T16:35:06.989Z","phase":"Phase 2","brief_title":"Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia","source_id_and_acronym":"NCT02782949","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • CXCL8 • IL1B","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • IL1B"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/04/2017","start_date":" 04/04/2017","primary_txt":" Primary completion: 10/06/2022","primary_completion_date":" 10/06/2022","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-30"},{"id":"3cc68517-997b-45c0-9418-e55247f24f07","acronym":"","url":"https://clinicaltrials.gov/study/NCT04414540","created_at":"2024-02-28T17:31:07.888Z","updated_at":"2024-07-02T16:35:17.528Z","phase":"Phase 2","brief_title":"Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients","source_id_and_acronym":"NCT04414540","lead_sponsor":"Trisha Wise-Draper","biomarkers":" IL6 • TNFA • CXCL8 • STAT3 • IL2 • IL10 • IL4 • NKG2D","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • STAT3 • IL2 • IL10 • IL4 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-28"},{"id":"f53f42a9-ecf7-4d67-b3af-c5c26772cf8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05255965","created_at":"2022-02-25T17:52:49.421Z","updated_at":"2024-07-02T16:35:18.923Z","phase":"","brief_title":"IL-8+ naïve T Cells as a Biomarker for Thymoma Identification","source_id_and_acronym":"NCT05255965","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-19"},{"id":"fcb310b1-7109-4950-b9ce-a0716eaa4d58","acronym":"FoCus","url":"https://clinicaltrials.gov/study/NCT06191120","created_at":"2024-01-04T16:18:07.968Z","updated_at":"2024-07-02T16:35:23.000Z","phase":"","brief_title":"FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype","source_id_and_acronym":"NCT06191120 - FoCus","lead_sponsor":"UMC Utrecht","biomarkers":" CXCL8 • ACTA2 • FAP • COL1A1 • MMP1 • RSPO3 • CXCL1 • CXCL14 • MMP3 • BMP4","pipe":" | ","alterations":" FAP expression","tags":["CXCL8 • ACTA2 • FAP • COL1A1 • MMP1 • RSPO3 • CXCL1 • CXCL14 • MMP3 • BMP4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2024-01-18"},{"id":"b12338e0-fa45-447b-8e22-dd27c2e163c2","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03829111","created_at":"2024-01-02T17:17:16.914Z","updated_at":"2024-07-02T16:35:24.804Z","phase":"Phase 1","brief_title":"CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer","source_id_and_acronym":"NCT03829111 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL6 • CXCL8","pipe":"","alterations":" ","tags":["IL6 • CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cdactin-O (CBM588)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 06/11/2024","primary_completion_date":" 06/11/2024","study_txt":" Completion: 06/11/2024","study_completion_date":" 06/11/2024","last_update_posted":"2024-01-01"},{"id":"34389e23-0b56-47ab-a3eb-c462a94da4bd","acronym":"MoSAIC","url":"https://clinicaltrials.gov/study/NCT05878236","created_at":"2023-05-26T15:07:14.057Z","updated_at":"2024-07-02T16:35:26.589Z","phase":"","brief_title":"iMmune SignAtures and Clinical outComes in AP","source_id_and_acronym":"NCT05878236 - MoSAIC","lead_sponsor":"Ohio State University","biomarkers":" IL6 • TNFA • CXCL8","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-12-11"},{"id":"f14f0a48-e7aa-49ba-8de8-e19e25558c06","acronym":"","url":"https://clinicaltrials.gov/study/NCT05599386","created_at":"2023-12-08T15:15:20.123Z","updated_at":"2024-07-02T16:35:26.732Z","phase":"","brief_title":"Predictors of Acute and Persistent Postoperative Pain in Lung Cancer Surgery","source_id_and_acronym":"NCT05599386","lead_sponsor":"Jannie Bisgaard Stæhr","biomarkers":" IL6 • TNFA • CXCL8","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 08/06/2023","primary_completion_date":" 08/06/2023","study_txt":" Completion: 08/06/2024","study_completion_date":" 08/06/2024","last_update_posted":"2023-12-08"},{"id":"4e146a44-d064-44ac-94c6-9a5142727e36","acronym":"ZUMA-12","url":"https://clinicaltrials.gov/study/NCT03761056","created_at":"2022-07-08T22:54:07.243Z","updated_at":"2024-07-02T16:35:30.615Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma","source_id_and_acronym":"NCT03761056 - ZUMA-12","lead_sponsor":"Kite, A Gilead Company","biomarkers":" IFNG • IL6 • CXCL8 • GZMB • IL5 • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • CXCL8 • GZMB • IL5 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 05/17/2021","primary_completion_date":" 05/17/2021","study_txt":" Completion: 10/12/2023","study_completion_date":" 10/12/2023","last_update_posted":"2023-11-02"},{"id":"16375f35-57e8-4891-ab8d-34d2a7ad1e54","acronym":"","url":"https://clinicaltrials.gov/study/NCT04495894","created_at":"2021-01-18T21:35:34.159Z","updated_at":"2024-07-02T16:35:32.024Z","phase":"Phase 1","brief_title":"Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma","source_id_and_acronym":"NCT04495894","lead_sponsor":"Emory University","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-24"},{"id":"9f71525a-859a-4973-afc8-cc6ff09d28a4","acronym":"UD","url":"https://clinicaltrials.gov/study/NCT04859218","created_at":"2021-04-26T12:52:46.599Z","updated_at":"2024-07-02T16:35:32.745Z","phase":"","brief_title":"Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?","source_id_and_acronym":"NCT04859218 - UD","lead_sponsor":"McMaster University","biomarkers":" IL6 • CXCL8 • CD40LG • CRP","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • CD40LG • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-19"},{"id":"e2727461-5321-42cb-8aa5-08f1add533c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06017661","created_at":"2023-08-30T14:08:54.257Z","updated_at":"2024-07-02T16:35:35.294Z","phase":"","brief_title":"Investigation of a Polyphenol-rich Preparation as Support for Oncology Patients Undergoing Gastrointestinal Tumor Resection","source_id_and_acronym":"NCT06017661","lead_sponsor":"AronPharma Sp. z o. o.","biomarkers":" IL6 • CXCL8","pipe":"","alterations":" ","tags":["IL6 • CXCL8"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2023-09-29"},{"id":"3f5c0ab2-0f8a-478a-9e82-1e103a467f1f","acronym":"MINDGAP","url":"https://clinicaltrials.gov/study/NCT04727593","created_at":"2021-01-27T13:54:10.090Z","updated_at":"2024-07-02T16:35:38.121Z","phase":"","brief_title":"The Modulatory Role of Internet MBCT on Extracellular Vesicles and Distress in Cancer Patients - Study Protocol","source_id_and_acronym":"NCT04727593 - MINDGAP","lead_sponsor":"Instituto Portugues de Oncologia, Francisco Gentil, Porto","biomarkers":" IL6 • MUC1 • CEACAM5 • CXCL8 • IL10","pipe":"","alterations":" ","tags":["IL6 • MUC1 • CEACAM5 • CXCL8 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 09/03/2021","start_date":" 09/03/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-09-04"},{"id":"f558dd72-ce2b-4a2b-8f9d-1822f6c0359b","acronym":"NCI-2014-02655","url":"https://clinicaltrials.gov/study/NCT01740557","created_at":"2021-01-18T07:37:08.655Z","updated_at":"2024-07-02T16:35:38.425Z","phase":"Phase 1/2","brief_title":"Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma","source_id_and_acronym":"NCT01740557 - NCI-2014-02655","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CXCL8 • NGFR • CXCR2","pipe":"","alterations":" ","tags":["CXCL8 • NGFR • CXCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 01/28/2015","start_date":" 01/28/2015","primary_txt":" Primary completion: 04/21/2023","primary_completion_date":" 04/21/2023","study_txt":" Completion: 04/21/2023","study_completion_date":" 04/21/2023","last_update_posted":"2023-08-31"}]